1346239-51-7

Upstream product

• 21739-92-4 5-bromo-2-chlorobenzoic acid 
• 21900-52-7 5-bromo-2-chloro-benzoyl chloride 
• 461432-22-4 (5-bromo-2-chlorophenyl)(4-ethyloxyphenyl)methanone 
• 1360568-68-8 (5-bromo-2-chlorophenyl)(4-hydroxyphenyl)methanone 
• 1404114-57-3 (5-bromo-2-chlorophenyl)(4-(2,2,2-trifluoroethoxy)phenyl)methanone 
• 1404114-58-4 2-(5-bromo-2-chlorophenyl)-2-(4-(2,2,2-trifluoroethoxy)phenyl)-1,3-dithiolane 
• 90-80-2 D-Glucono-1,5-lactone 
• 1404114-60-8 C₂₂H₂₂ClF₅O₇ 

Relevant academic research and scientific papers

Inhibitor of Sodium-Dependent Glucose Transport Protein and Preparation Method Therefor and Use Thereof

Disclosed is a compound of formula I, or a pharmaceutically acceptable salt, solvate, polymorph, enantiomer or racemic mixture thereof, wherein R1 and R2 are each independently hydrogen, —OH, alkyl, —CF3, —OCHF2, —OCF3 or halogen; R3 is cycloalkyl, —OCH2CF3, —OCH2CHF2, —OCH2CH2F or —OCH2CH3; R4 is hydrogen, —OH, —O aryl, —OCH2 aryl, alkyl, cycloalkyl, —CF3, —OCHF2, —OCF3, —OCH2CF3, —OCH2CHF2, —OCH2CH2F or halogen; A is —CX1X2, wherein X1 and X2 are each independently H, F and Cl, and when both X1 and X2 are H, R3 is not —OCH2CH3. The compound has an activity of inhibitors of sodium-dependent glucose transport protein. Also disclosed is a method for preparing the compound, a pharmaceutical composition comprising the compound, use of the compound and pharmaceutical composition thereof in preparing medicaments of SGLT2 inhibitors and treating related diseases.